News

Amsterdam Molecular Therapeutics (AMT) has reported an increase in operating loss to E9.9m for the six months ended June 30, 2009, from E9.1m for the same period in

Oxygen has received approval to begin a phase II, dose escalation, clinical trial in Switzerland for use of Oxycyte in traumatic brain injury (TBI). The company has named

King Pharmaceuticals (King) has received FDA approval for Embeda (morphine sulfate and naltrexone hydrochloride) extended release capsules for oral use. Embeda, a long-acting opioid that is designed to

FDA has released its official and final report regarding the agency’s review of allegations made in a July newspaper article concerning mylan’s Morgantown, W.Va., manufacturing facility. The newspaper

Interleukin Genetics has posted revenue from continuing operations for the three months ended June 30, 2009 at $0.2m, compared to $0.5m for the same period in the prior

Amgen will summarize data from the submitted Biologic License Applications (BLAs) at a meeting with the FDA’s Advisory Committee for Reproductive Health Drugs (ACRHD). BLAs, for denosumab for

Skystar Bio-Pharmaceutical reports gross profit for the second quarter of $3.3m, up 42% from the second quarter of 2008. Gross margin for the quarter was 52.6%, compared to

Tianyin has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Sanqi Tablets in dosage form of 0.5gm/tablet, and Yinqiao Jiedu Tablets in dosage

Nutra Pharma has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has filed a patent for a novel composition and method for oral delivery of cobra venom, for